Category: Schizophrenia treatment

With a half-life ranging from 84 to 139 days, the medication Paliperidone Trinza provides prolonged therapeutic levels for patients with schizophrenia. This extended duration is a key feature of the long-acting injectable (LAI) formula, which is designed to improve medication adherence and reduce the frequency of injections.

In September 2024, the FDA approved Cobenfy, representing the first new class of medicine for schizophrenia in decades. This oral prescription medication is not a single drug but a combination product, which is why the question of what is the generic name for COBENFY is best answered by listing its two active components.